Skip to main content

Table 1 Patient baseline demographics and disease characteristics

From: Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

Characteristic

N = 43

Median age, years (range)

63 (38–79)

Male, n (%)

27 (63)

Asian ethnicity, n (%)

 

 Chinese

20 (47)

 Korean

16 (37)

 Other

7 (16)

ECOG performance status, n (%)

 

 0

24 (56)

 1

17 (40)

 2

2 (5)

ISS stage, n (%)

 

 I

10 (23)

 II

18 (42)

 III

13 (30)

 Unknown

2 (5)

MM subtype, n (%)

 

 IgG

27 (63)

 IgA

5 (12)

 Kappa light chain

5 (12)

 Lambda light chain

2 (5)

 Biclonal

1 (2)

 Unknown

3 (7)

Lytic bone lesions, n (%)

 

 Yes

32 (74)

 No

10 (23)

 Unknown

1 (2)

Median time since initial diagnosis to first dose of ixazomib, months (range)

36.3 (8–116)

Number of prior therapies, n (%)

 

 1

20 (47)

 2

10 (23)

 3

12 (29)

 >3a

1 (2)

Prior therapy for MM, n (%)

 

 Corticosteroids

43 (100)

 Bortezomib

32 (74)

 Thalidomide

30 (70)

 Lenalidomide

9 (21)

 Carfilzomib

2 (5)

Prior transplant, n (%)

21 (49)

  1. ECOG Eastern Cooperative Oncology Group, ISS International Staging System, MM multiple myeloma
  2. aOne patient had received five prior therapies